Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
BIOGEN INC.
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-39.4% vs price
Base Case (Median)
-14.2% vs price
Bull Case (75th pct.)
42.1% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $705.77 | 222.1% | High (40%) |
| PE Comparable | $126.42 | -42.3% | Medium (25%) |
| Graham Number | $125.13 | -42.9% | Medium (40%) |
| EV/EBITDA | $151.59 | -30.8% | Medium (20%) |
| EV/FCF | $340.44 | 55.4% | Medium (20%) |
| Earnings Power Value | $224.16 | 2.3% | Medium (50%) |
Based on 6 out of 7 methods, BIIB appears fairly valued at the current price of $219.10. The base case fair value of $187.88 implies 14.2% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.